INTERVIEW

Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.

November 28, 2014
US biotech major Gilead Sciences Inc. officially announced its plan to set foot in the Japanese market in October last year. This year it submitted new drug applications for sofosbuvir and a fixed-dose combination of ledipasvir and sofosbuvir, both for…

To read the full story

INTERVIEW

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…